ST Pharm, which recorded a deficit in the first half of the year, is expected to see a rebound in performance in the second half. On the 26th, the securities industry projected that ST Pharm's…

“60,000 Celltrion shareholders firmly oppose the merger with Celltrion Pharm, which undermines shareholder value. We strongly urge the company to swiftly announce a clear and detailed stance on the…

GC Biopharma Corp's new immune globulin drug 'Alyglo' is set to enter the U.S. market after 8 years of efforts. According to the pharmaceutical industry on the 25th, GC Biopharma plans to officially…

Daewoong Pharmaceutical has unveiled its next growth strategy, the 'One Product, one Trillion Won Plan.' The goal is to achieve sales of over 1 trillion won (approx. $770 million) for three flagship…

Samsung Bioepis announced on the 23rd that it has received approval from the U.S. Food and Drug Administration (FDA) for 'Epysqli' (active ingredient: Eculizumab), a high-cost treatment for rare…

Celltrion announced on the 23rd that its third plant, located in Songdo, Incheon, is undergoing final validation before commencing commercial production. Validation is a critical procedure that…

Samsung Electronics has decided to effectively recall its new product, 'Buds 3 Pro', following criticisms of manufacturing and finishing defects. The company recently announced on its website, "We…

GC WellBeing Corporation Expected to See Stock Price Rise in H2 with Stable Sales Growth in Chinese Market Analysts predict that GC WellBeing Corporation will see a stable increase in sales and a…

The focus of global clinical trials is shifting from Europe to the United States and China, according to a recent market analysis. IQVIA, a global healthcare consulting firm, released a…

SK Biopharm is expected to continue its performance growth in the second half of the year, driven by the stable sales growth of its epilepsy treatment, Cenobamate (marketed in the U.S. as Xcopri).…